Regular ArticlesIn Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor Prognosis
Under an Elsevier user license
open archive
Cited by (0)
Supported by R33 CA 110511 Predicting Metastasis to Lymph Nodes (in breast cancer) to D.L.R.
D.L.R. declares a duality of interest, as a founder, consultant, and stockholder of a biotech company called HistoRx. This company was founded by Yale and is the exclusive Yale licensee of the AQUA® technology developed in Dr. Rimm's lab. R.L.C. is also a stockholder in this company and serves as a consultant.
Supplemental material for this article can be found on http://ajp.amjpathol.org.
Copyright © 2010 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.